Claims

[Claim 1]

Use of Romiplostim as an active ingredient in the manufacture of a pharmaceutical composition for treating aplastic anemia, wherein the pharmaceutical composition is to be administered subcutaneously once a week,

wherein the pharmaceutical composition is to be administered at 10 μg Romiplostim/kg/week for 4 weeks from the start of administration, and is to be administered at more than 10 μg Romiplostim/kg/week and a maximum of 20 μg Romiplostim/kg/week from week 5, and

wherein a dose increment from week 5 is 5 μg Romiplostim/kg.

[Claim 2]

The use according to claim 1, wherein the same dose is to be maintained for 4 weeks or more after a dose change.

[Claim 3]

The use according to claim 1, wherein the pharmaceutical composition is to be administered at 15 μg Romiplostim/kg/week from week 5 to week 8 and is to be administered at a maximum of 20 μg Romiplostim/kg/week from week 9, and

wherein the same dose is to be maintained for 4 weeks or more after a dose change.

[Claim 4]

The use according to claim 1, wherein the pharmaceutical composition is to be administered at 15 μg Romiplostim/kg/week from week 5, and

wherein the same dose is to be maintained for 4 weeks or more after a dose change.

[Claim 5]

Use of Romiplostim as an active ingredient in the manufacture of a pharmaceutical composition for treating aplastic anemia, wherein the pharmaceutical composition is to be administered subcutaneously once a week, and

wherein the pharmaceutical composition is to be administered at 10 μg Romiplostim/kg/week for 4 weeks from the start of administration, and a dose increment of Romiplostim from week 5 is 5 μg Romiplostim/kg.

[Claim 6]

The use according to claim 5, wherein the same dose is to be maintained for 4 weeks or more after a dose change.